Sign In
Buy NEO
$15.29
-0.590 (-3.72%)
At Close: Jul 31, 2026
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
07:05am, Monday, 15'th Dec 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
NeoGenomics to Present New ctDNA Research at SABCS 2025
07:05am, Wednesday, 10'th Dec 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
AerCap Signs Lease Agreements with New Customer My Freighter for Two New Airbus A321NEO Aircraft
04:00am, Tuesday, 09'th Dec 2025
DUBLIN , Dec. 9, 2025 /PRNewswire/ -- AerCap Holdings N.V. ("AerCap" or the "Company") (NYSE: AER) today announced it has signed lease agreements for two new Airbus A321neo aircraft with My Freighter
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
08:05am, Monday, 08'th Dec 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
UK: TotalEnergies Merges Its Upstream Business with NEO NEXT, Creating the Largest Independent Oil and Gas Producer in the UK
03:08am, Monday, 08'th Dec 2025
PARIS--(BUSINESS WIRE)--TotalEnergies has signed an agreement with NEO NEXT Energy Limited (NEO NEXT) under which TotalEnergies will merge its Upstream business with NEO NEXT and become the leading sh
Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $13.11
02:34am, Tuesday, 18'th Nov 2025
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have earned an average rating of "Hold" from the sixteen research firms that are covering the stock, Marketbeat reports. One investment anal
Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript
12:41pm, Friday, 14'th Nov 2025
Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP
CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pione
NeoGenomics to Participate in Upcoming Investor Conferences
07:05am, Thursday, 06'th Nov 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
12:51pm, Thursday, 30'th Oct 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
03:11pm, Tuesday, 28'th Oct 2025
NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren S
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Oct 2025
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics Reports Third Quarter 2025 Results
07:05am, Tuesday, 28'th Oct 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.
NEO Home Loans Appoints Bri Lees as Head of Marketing to Lead Brand and Growth Across Advisor-First Platform
09:00am, Thursday, 23'rd Oct 2025
NEW YORK--(BUSINESS WIRE)-- #NEOHomeLoans--NEO Home Loans powered by Better (NASDAQ: BETR), has appointed Bri Lees as Head of Marketing, advancing the company's next phase of growth and deepening the
SYDNEY, AUSTRALIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune d
